Nature of the Event

The company has agreed to acquire 1,24,64,000 equity shares of ₹10 each, representing a 76% stake in an unnamed target pharmaceutical company based in Visakhapatnam (Vizag), Andhra Pradesh. The acquisition includes the target's business, manufacturing plant, and team. The transaction is subject to the successful completion of due diligence and obtaining necessary regulatory approvals. Upon completion, the target company will become a subsidiary of Sudarshan Pharma Industries Limited.

Key Quantitative Figures

  • Shares to be Acquired: 1,24,64,000 equity shares
  • Stake: 76% of the target's paid-up equity share capital
  • Target's Historical Turnover:
  • FY 2025-26: ₹15,437 Lakhs
  • FY 2024-25: ₹15,355 Lakhs
  • FY 2023-24: ₹19,247 Lakhs
  • Manufacturing Capacity: The plant has a total manufacturing capacity of 576.10 KL, contained within 4 manufacturing blocks.

Consideration Structure

The acquisition will be financed through a combination of cash and equity. The consideration includes a cash subscription and an issuance of 40,00,000 (40 Lakh) shares of Sudarshan Pharma Industries Limited, which are to be offered by the company's promoters. The final cost of acquisition will be determined based on the outcome of the due diligence process.

Purpose and Rationale

The stated object of the acquisition is to achieve backward integration and launch a complete end-to-end manufacturing capability within Sudarshan Pharma Industries Limited.

Regulatory and Approval Status

The disclosure confirms that this acquisition does not constitute a related party transaction, and no promoters, promoter groups, or group companies have any interest in the target entity. The document states that governmental or regulatory approvals are "Not Applicable" for this transaction.

Accreditations of the Target

The target manufacturing plant holds several key accreditations, including from the US FDA, WHO Geneva, Anvisa, the Drugs Control Administration (DCA) of the Government of Andhra Pradesh, and relevant ISO standards.

Timeline

The indicative timeline for the completion of the acquisition is 10th October 2026.

Disclosure Reference

This intimation is made in compliance with Regulation 30 of the SEBI LODR Regulations, 2015, and with reference to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024.

#SudarshanPharma #Acquisition #M&A #SEBIDisclosure #Regulation30 #Pharmaceuticals #Neutral